CSPC Innovation Pharmaceutical Co Ltd SZSE:300765:
SAYS CO PLANS TO SEEK HONG KONG LISTING
CSPC Innovation Pharmaceutical Plans To Seek Hong Kong Listing
Earlier from Cspc Innovation Pharmaceutical Co., Ltd. Class A
- CSPC Innovation Pharmaceutical: Revenue up, but net loss driven by R&D surge; biopharma growth and global deals highlight H1
- CSPC Innovation Pharmaceutical: Revenue fell and losses widened in Q1 2025 amid R&D surge and raw material price drops
- CSPC Innovation Pharmaceutical: Net profit plunged 87.63% as R&D spending rose and caffeine prices dropped, but biopharma sales soared 153%
- CSPC Innovation Pharmaceutical: Revenue and profit fell significantly amid market headwinds and rising R&D costs